WCM/EADO 2021 | CMP-001 for PD-1 refractory patients with melanoma

Art Krieg, MD, Checkmate Pharmaceuticals, Cambridge, MA, outlines the potential of CMP-001 as an alternative therapy for patients who do not respond to PD-1 targeted checkpoint inhibitor therapy. CMP-001 is a virus-like particle that is a CpGA DNA toll-like receptor 9 agonist which triggers a strong T-cell response. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.